With the entries for the 2019 competition well underway, PharmaTimes have seen a large number of industry leading companies putting their best individuals and teams forward.
News
LEO Pharma completes Bayer prescription dermatology business acquisition
Under the terms of the agreement, LEO Pharma has now acquired the global product rights for Bayer’s global prescription dermatology business with the exception of Afghanistan and Pakistan.
Children’s hospices to receive £25m a year as part of NHS Long Term Plan
NHS England’s hospice grant programme currently provides £12 million a year for children’s hospices.
Obesity now leading cause of four cancers
Cancer Research UK has launched a new public awareness campaign and is urging the government to act, as the number of people who are obese outnumbers those who smoke two to one
ViiV secures EU nod for HIV therapy Dovato
Availability of the two-drug regimen is considered a significant development for people with the condition
NICE approves CDF funding for Sanofi’s Libtayo
Around 560 patients per year with cutaneous squamous cell carcinoma are thought to be eligible for treatment with the drug in England
Mundipharma picks up rights to Herceptin biosimilar Tuznue
The deals allows the firm to market and distribute the drug in selected European countries following its approval
NICE pushes social prescribing for dementia
Health and social care secretary Matt Hancock says he “Wholeheartedly endorses” the quality standard.
Cancer Research UK, SV Health Investors team up for speedy drug development
Cancer Research UK will collaborate closely with SV to identify promising, novel research from within the charity’s network that could be rapidly developed.
Libtayo bags EU approval for skin cancer
The European Commission has granted conditional marketing authorisation for the drug for patients who are not candidates for curative surgery or curative radiation.
Research supports better integration of patient voice in health technology assessments
The research will help ensure new treatments reflect the needs and preferences of patients and family members living with myeloma and other conditions.
RCGP responds to primary care network roll-out
Professor Helen Stokes-Lampard, chair of the Royal College of GPs believes the newly-launched primary care networks have “undeniable benefits.”
Wrong information creating ‘dangerous screening gap’ in cervical cancer
The NHS reminds the public that any sexual activity can pass on the virus which causes the vast majority of cervical cancers.
AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Parkinson’s UK to inject £1m into drug development
The charity is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells.
